1 / 8

Irritable Bowel Syndrome (IBS) Treatment Market Is Expected To See Huge Growth.

According to our latest study on u201cIrritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 u2013 COVID-19 Impact and Global Analysis u2013 by Type, Product, and Distribution Channel,u201d the market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

nikhilghodse94
Télécharger la présentation

Irritable Bowel Syndrome (IBS) Treatment Market Is Expected To See Huge Growth.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Irritable Bowel Syndrome (IBS) Treatment Market Global Analysis and Forecast to 2028 Published Date : May 2021 Email: sales@theinsightpartners.com

  2. Email: sales@theinsightpartners.com Report Studies  Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M)], Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies) 2

  3. Email: sales@theinsightpartners.com Irritable Bowel Syndrome (IBS) Treatment Market Overview  The Irritable Bowel Syndrome (IBS) Treatment Market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028.  The major factors such as the increasing prevalence of irritable bowel syndrome diseases and rising research & development activities drive the market growth. However, the limited number of product availability and treatment inefficiency restrain the market growth. IBS is a common chronic condition that affects the abdominal organ, large intestine. It is also known as spastic colon, mucous colitis, irritable colon, and spastic colitis. The condition is much different than inflammatory bowel disease. It shows symptoms such as cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both at the same. If the symptoms are mild, they can be managed by changing stress, lifestyle, and diet. On the other side, severe symptoms are treated with medication and counseling. 3

  4. Email: sales@theinsightpartners.com Key Segment Market Segment By Type:-  By Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M))  Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others)  End-User (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies) Download Sample Here 4

  5. Email: sales@theinsightpartners.com $50,000 Irritable Bowel Syndrome (IBS) Treatment Market Value $40,000 $30,000 CAGR of 10.1% $20,000 (2021 - 2028) $10,000 $0 20XX 20XX 20XX 20XX 20XX Download Sample 5

  6. Email: sales@theinsightpartners.com Company Profiles  Ironwood Pharmaceuticals, Inc.  AbbVie.  Sebela Pharmaceuticals, Inc.  Takeda Pharmaceutical Company Limited  Alfasigma S.p.A.  Astellas Pharma Inc.  AstraZeneca  Synthetic Biologics, Inc.  Bausch + Lomb Incorporated  Lannett Company Inc Download Sample Here 6

  7. Email: sales@theinsightpartners.com By Geography  North America (the US, Canada, and Mexico)  Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe)  Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific)  Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa)  South & Central America (Brazil, Argentina, and the Rest of South & Central America). 7

  8. THANK YOU! Phone : +1-646-491-9876 E-Mail : sales@theinsightpartners.com

More Related